Patents by Inventor Masad Damha
Masad Damha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230192751Abstract: There is provided herein, processes for synthesizing oligonucleotides using mechanochemical force to induce the formation of internucleotide linkages.Type: ApplicationFiled: May 26, 2021Publication date: June 22, 2023Inventors: Masad DAMHA, Tomislav FRISCIC, Daniel O'Reilly, James THORPE
-
Patent number: 11306305Abstract: The present disclosure provides CRISPR/Cas9 ribonucleoprotein compositions comprising chemically modified CRISPR RNA (crRNA) guide and trans-acting CRISPR RNA (tracrRNA) components. Methods of using the disclosed CRISPR/Cas9 ribonucleoprotein compositions are also provided.Type: GrantFiled: September 22, 2017Date of Patent: April 19, 2022Assignees: Board of Trustees of Southern Illinois UniversityInventors: Keith Gagnon, Masad Damha, Elise Malek-Adamian, Maryam Habibian, Daniel Timothy O'Reilly, Zachery Kartje
-
Publication number: 20210355488Abstract: A CRISPR inhibitor molecule is provided, comprising an artificial nucleic acid construct having a first polynucleotide, the inhibitor molecule capable of establishing several points of contact with a CRISPR protein and high binding affinity thereto, is provided. The first polynucleotide may comprise a sequence selected from the group consisting of: a polynucleotide that interacts with a protospacer adjacent motif (PAM)-interaction (PI) domain of a CRISPR-associated (Cas) protein, a polynucleotide that interacts with a guide sequence of a crRNA or an equivalent position of a single-guide RNA, and a polynucleotide that interacts with a repeat region of a tracrRNA or an equivalent position of a single-guide RNA. The CRISPR inhibitor molecule may also comprise a second polynucleotide and a linker. Methods of using the CRISPR inhibitor molecule in therapeutic agent selection and creation, as well as part of a therapeutic treatment, are also provided.Type: ApplicationFiled: September 30, 2019Publication date: November 18, 2021Inventors: Keith T. Gagnon, Masad Damha, Christopher Barkau, Daniel O'Reilly
-
Publication number: 20190185844Abstract: The present disclosure provides CRISPR/Cas9 ribonucleoprotein compositions comprising chemically modified CRISPR RNA (crRNA) guide and trans-acting CRISPR RNA (tracrRNA) components. Methods of using the disclosed CRISPR/Cas9 ribonucleoprotein compositions are also provided.Type: ApplicationFiled: September 22, 2017Publication date: June 20, 2019Applicants: Board of Trustees of Southern lllinois University, The Royal Institution for the Advancement of Learning/McGill UniversityInventors: Keith GAGNON, Masad DAMHA, Elise MALEK-ADAMIAN, Maryam HABIBIAN, Daniel O'REILLY, Zachery KARTJE
-
Patent number: 10287313Abstract: The present invention is directed to RNA monomers comprising O-acetal levulinyl protecting groups at the 2? and/or the 5?-hydroxy functionalities of the ribose moiety. Said monomers may be incorporated into oligoribonucleotides or RNA polynucleotides. Furthermore, the invention is directed to methods for the synthesis of said RNA monomers, oligoribonucleotides and RNA polynucleotides, as well as methods for their deprotection and methods for the use of said compounds and compositions comprising said compounds. In particular, such compounds and compositions comprising them are used in methods for light-directed synthesis of RNA microarrays.Type: GrantFiled: December 29, 2015Date of Patent: May 14, 2019Assignees: The Royal Institution for the Advancement of Learning/McGill University, Wisconsin Alumni Research FoundationInventors: Masad Damha, Jeremy Lackey, Debbie Mitra, Marvin Wickens, Franco Cerrina, Mark Somoza
-
Publication number: 20160340382Abstract: The present invention is directed to RNA monomers comprising O-acetal levulinyl protecting groups at the 2? and/or the 5?-hydroxy functionalities of the ribose moiety. Said monomers may be incorporated into oligoribonucleotides or RNA polynucleotides. Furthermore, the invention is directed to methods for the synthesis of said RNA monomers, oligoribonucleotides and RNA polynucleotides, as well as methods for their deprotection and methods for the use of said compounds and compositions comprising said compounds. In particular, such compounds and compositions comprising them are used in methods for light-directed synthesis of RNA microarrays.Type: ApplicationFiled: December 29, 2015Publication date: November 24, 2016Applicants: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Masad Damha, Jeremy Lackey, Debbie Mitra, Marvin Wickens, Franco Cerrina, Mark Somoza
-
Patent number: 9493772Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.Type: GrantFiled: May 22, 2014Date of Patent: November 15, 2016Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITYInventors: Kevin Petrecca, Masad Damha, Glen Deleavey
-
Patent number: 9249175Abstract: The present invention is directed to RNA monomers comprising O-acetal levulinyl protecting groups at the 2? and/or the 5?-hydroxy functionalities of the ribose moiety. Said monomers may be incorporated into oligoribonucleotides or RNA polynucleotides. Furthermore, the invention is directed to methods for the synthesis of said RNA monomers, oligoribonucleotides and RNA polynucleotides, as well as methods for their deprotection and methods for the use of said compounds and compositions comprising said compounds. In particular, such compounds and compositions comprising them are used in methods for light-directed synthesis of RNA microarrays.Type: GrantFiled: September 4, 2009Date of Patent: February 2, 2016Assignees: The Royal Institute for the Advancement of Learning/McGill University, Wisconsin Alumni Research FoundationInventors: Masad Damha, Jeremy Lackey, Debbie Mitra, Marvin Wickens, Franco Cerrina, Saima A. Akhtar, Mark Somoza
-
Publication number: 20140343124Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.Type: ApplicationFiled: May 22, 2014Publication date: November 20, 2014Applicant: The Royal Institution for The Advancement of Learning/McGill UniversityInventors: Kevin PETRECCA, Masad DAMHA, Glen DELEAVEY
-
Patent number: 8765708Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.Type: GrantFiled: May 18, 2011Date of Patent: July 1, 2014Inventors: Kevin Petrecca, Masad Damha, Glen Francis Deleavey
-
Publication number: 20130197057Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.Type: ApplicationFiled: May 18, 2011Publication date: August 1, 2013Inventors: Kevin Petrecca, Masad Damha, Glen Francis Deleavey
-
Publication number: 20120178638Abstract: The present invention is directed to RNA monomers comprising O-acetal levulinyl protecting groups at the 2? and/or the 5?-hydroxy functionalities of the ribose moiety. Said monomers may be incorporated into oligoribonucleotides or RNA polynucleotides. Furthermore, the invention is directed to methods for the synthesis of said RNA monomers, oligoribonucleotides and RNA polynucleotides, as well as methods for their deprotection and methods for the use of said compounds and compositions comprising said compounds. In particular, such compounds and compositions comprising them are used in methods for light-directed synthesis of RNA microarrays.Type: ApplicationFiled: September 4, 2009Publication date: July 12, 2012Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Masad Damha, Jeremy Lackey, Debbie Mitra, Marvin Wickens, Franco Cerrina, Saima A. Akhtar, Mark Somoza
-
Publication number: 20090298913Abstract: Small interfering ribonucleic acid duplexes that inhibit gene expression containing at least one arabinose modified nucleotide are provided. Preferably, the duplexes contain ribonucleotides at least one arabinose modified nucleotide is 2?-deoxy-2?-fluoroarabinonucleotide (FANA) nucleotide.Type: ApplicationFiled: October 26, 2006Publication date: December 3, 2009Applicant: TOPIGEN PHARMACEUTICALS INC.Inventors: Masad Damha, Nicolay Ferrari
-
Publication number: 20050233455Abstract: Oligonucleotides having an internal acyclic linker residue, and the preparation and uses thereof, are described. Such uses include the preparation of acyclic linker-containing antisense oligonucleotides, and their use for the prevention or depletion of function of a target nucleic acid of interest, such as RNA, in a system. Such a prevention or depletion of function includes, for example, the prevention or inhibition of the expression, reverse transcription and/or replication of the target nucleic acid, as well as the cleavage/degradation of the target nucleic acid. Accordingly, an oligonucleotide of the invention is useful for analytical and therapeutic methods and uses in which the function of a target nucleic acid is implicated, as well as a component of commercial packages corresponding to such methods and uses.Type: ApplicationFiled: October 29, 2002Publication date: October 20, 2005Inventors: Masad Damha, Ekaterina Viazovkina, Maria Mangos, Michael Parniak, Kyung-Lyum Min
-
Publication number: 20050142535Abstract: The invention relates to oligonucleosides having alternating segments of sugar-modified nucleosides and 2?-deoxynucleosides, and uses thereof. The invention further relates to oligonucleotides having alternating segments of sugar-modified nucleotides and 2?-deoxynucleotides, and uses thereof. Such uses include the preparation of antisense oligonucleotides and their use for the prevention or depletion of function of a target nucleic acid of interest, such as an RNA, in a system. Accordingly, an oligonucleotide of the invention is useful for therapeutic, analytical and diagnostic methods and uses, as well as a component of compositions and commercial packages corresponding to such methods and uses.Type: ApplicationFiled: January 31, 2003Publication date: June 30, 2005Inventors: Masad Damha, Michael Parniak
-
Publication number: 20030157538Abstract: A biosensor for direct analysis of nucleic acid hybridization by use of an optical fiber functionalized with nucleic acid molecules and fluorescence transduction is disclosed. Nucleic acid probes are immobilized onto the surface of optical fibers and undergo hybridization with complementary nucleic acids introduced into the local environment of the sensor. Hybridization events are detected by the use of fluorescent compounds which bind into nucleic acid hybrids. The invention finds uses in detection and screening of genetic disorders, viruses, and pathogenic microorganisms. Biotechnology applications include monitoring of gene cultures and gene expression and the effectiveness (e.g. dose-response) of gene therapy pharmaceuticals. The invention includes biosensor systems in which fluorescent molecules are connected to the immobilized nucleic acid molecules. The preferred method for immobilization of nucleic acids is by in-situ solid phase nucleic acid synthesis.Type: ApplicationFiled: January 7, 2003Publication date: August 21, 2003Inventors: Ulrich J. Krull, Paul A. Piunno, Robert H.E. Hudson, Masad Damha, Andre H. Uddin
-
Patent number: 6503711Abstract: A biosensor for direct analysis of nucleic acid hybridazation by use of an optical fiber functionalized with nucleic acid molecules and fluorescence transduction is disclosed. Nucleic acid probes are immobilized onto the surface of optical fibers and undergo hybridization with complementary nucleic acids introduced into the local environment of the sensor. Hybridization events are detected by the use of fluorescent compounds which bind into nucleic acid hybrids. The invention finds uses in detection and screening of genetic disorders, viruses, and pathogenic micoorganisms. Biotechnology applications include monitoring of gene cultures and gene expression and the effectiveness (e.g. dose-response) of gene therapy pharmaceuticals. The invention includes biosensor systems in which fluorescent molecules are connected to the immobilized nucleic acid molecules. The preferred method for immobilization of nucleic acids is by in situ solid phase nucleic acid synthesis.Type: GrantFiled: February 16, 2000Date of Patent: January 7, 2003Inventors: Ulrich J. Krull, Paul A. Piunno, Robert H. E. Hudson, Masad Damha, Andre H. Uddin